Navigation Links
Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
Date:10/23/2008

-Sapirstein to Present Company Overview-

PRINCETON, N.J. and SAN DIEGO, Oct. 23 /PRNewswire/ -- Tobira Therapeutics, Inc., a company focused on the development of medicines with novel mechanisms of actions for infectious diseases, today announced it will present a corporate overview at the 2008 BIO Investor Forum. James Sapirstein, Chief Executive Officer and President will summarize the current status of the company including the status of TBR-652, a CCR5 antagonist in development for HIV-1 infection in adults. The presentation is scheduled for October 30, 2008 at 9:00 AM PST at The Palace Hotel, Two New Montgomery Street, San Francisco, Calif.

"We are delighted to share the growth Tobira Therapeutics, Inc. has experienced in the last 18 months at the BIO Investor Forum," said James Sapirstein. "This is a unique opportunity to review the great potential that we have to offer." Tobira Therapeutics is a clinical stage company and is not developing new technologies. The company is expanding its pipeline by being the partner of choice for suppliers, researchers, and alliance partners. A key component of Tobira's strategy is to acquire global rights to additional product candidates in infectious diseases, while continuing to develop and commercialize new products and line extensions.

The BIO Investor Forum will feature more than 190 public and venture-stage company presentations, in addition to drug and technology therapeutic workshops, breakout sessions, one-on-one investor meetings, and networking with industry executives and investors.

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

Contact:

Tobira Therapeutics Inc.

Antoinette Bobbitt, Senior Director, Corporate and Business Development

abobbitt@tobiratherapeutics.com Tel: +1 609-897-1102

http://www.tobiratherapeutics.com


'/>"/>
SOURCE Tobira Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Senior Management Team
2. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
3. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
4. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc. Announces Reverse Stock Split
7. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
10. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
11. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can fast-track sample ... acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. ... the relationship between insulin and other relevant biomarkers can be extensively studied through ...
(Date:2/23/2017)... LOS ANGELES , Feb. 23, 2017  Capricor Therapeutics, ... cardiac and other medical conditions, today announced that Linda Marbán, ... at two upcoming investor conferences: Cowen ... 2017 at 10:00 am ET Boston, MA ... 14, 2017 at 9:00 am PT (12:00 pm ET) ...
(Date:2/23/2017)... DIEGO and SAN FRANCISCO ... a privately-held regenerative medicine company, and Beyond Type 1, ... with type 1 diabetes, today announced a grant from ... a functional cure for type 1 and other insulin-requiring ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:2/22/2017)... 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics ... biopharmaceutical products for companion animals, will host a live conference ... to discuss financial results from the fourth quarter and full ... and investors may access the audio webcast or ... ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
Breaking Biology News(10 mins):